Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Richard M. Goldberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0308-8223; OpenAlex author ID A5080788977. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers

Papers 8

  1. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Co-author DOI 10.1158/1078-0432.ccr-22-0275↗
  2. The evolving role of radiation in pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1060885↗
  3. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  4. Therapeutic advances in pancreatic cancer: miles to go before we sleep. First author DOI 10.1093/jnci/dju439↗
  5. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Co-author DOI 10.1158/1078-0432.ccr-13-0926↗
  6. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 8030… Co-author DOI 10.1002/cncr.26270↗
  7. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Co-author DOI 10.1158/1078-0432.ccr-11-1387↗
  8. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B… Co-author DOI 10.1002/cncr.25742↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andreas Seeber · 2 shared papers, 2020–2022 · strength 0.19
  2. Florian Kocher · 2 shared papers, 2020–2022 · strength 0.19
  3. Alberto Puccini · 2 shared papers, 2020–2022 · strength 0.19
  4. Heinz‐Josef Lenz · 2 shared papers, 2020–2022 · strength 0.19
  5. Michael J. Hall · 2 shared papers, 2020–2022 · strength 0.19
  6. Wolfgang Michael Korn · 2 shared papers, 2020–2022 · strength 0.19
  7. John Lindsay Marshall · 2 shared papers, 2020–2022 · strength 0.19
  8. Anthony Frank Shields · 2 shared papers, 2020–2022 · strength 0.19
  9. Hassan A. Hatoum · 1 shared paper, 2022 · strength 0.17
  10. Nadia Karen Malik · 1 shared paper, 2022 · strength 0.17
  11. Midhun Malla · 1 shared paper, 2022 · strength 0.17
  12. Sarbajit Mukherjee · 1 shared paper, 2022 · strength 0.17
  13. Angelica Petrillo · 1 shared paper, 2022 · strength 0.11
  14. Johannes Haybaeck · 1 shared paper, 2022 · strength 0.11
  15. Mohamed E. Salem · 1 shared paper, 2022 · strength 0.11
  16. Emil Lou · 1 shared paper, 2022 · strength 0.11
  17. Tanios Bekaii‐Saab · 1 shared paper, 2015 · strength 0.11
  18. Hedy Lee Kindler · 3 shared papers, 2012–2013 · strength 0.09
  19. Axel F. Grothey · 1 shared paper, 2020 · strength 0.09
  20. Gilbert Spizzo · 1 shared paper, 2020 · strength 0.09
  21. Wafik S. El‐Deiry · 1 shared paper, 2020 · strength 0.09
  22. Philip A. Philip · 1 shared paper, 2020 · strength 0.09
  23. Alan Paul Venook · 2 shared papers, 2012–2013 · strength 0.07
  24. Herbert I. Hurwitz · 2 shared papers, 2012–2013 · strength 0.06
  25. Kouros Owzar · 2 shared papers, 2012 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.